Angiofibroma

• EMA approval · 2026-08-06
  EMA Authorised: Hyftor (sirolimus) — Plusultra pharma GmbH

  Sirolimus (Hyftor) from Plusultra pharma GmbH has been authorised for use in angiofibroma and tuberous sclerosis, designated as an orphan me…

• EMA approval · 2025-07-04
  EMA Authorised: Hyftor (sirolimus) — Plusultra pharma GmbH

  The EMA authorised Hyftor (sirolimus) by Plusultra pharma GmbH for angiofibroma and tuberous sclerosis complex with orphan medicine status.

• CLINICAL_TRIALS trial_result · 2019-02-20
  Clinical Trial Update: Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex [Phase 3]

  This entry reports the long-term results of a Phase 3 trial of topical sirolimus for angiofibromas in patients with tuberous sclerosis compl…